RA Capital Management 13F holdings, Q4 2015
Holdings as of December 31, 2015 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 37 US equity positions worth $1.0bn in its Q4 2015 13F filing. The largest position was ACHILLION PHARMACEUTICALS INC at 12.0% of the reported book, followed by WVE and DYAX CORP. Against the Q3 2015 filing, it opened 6 new positions, added to 8 and reduced 13 among the top 37 holdings.
What did RA Capital Management own in Q4 2015? Top 37 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2015 |
|---|---|---|---|---|---|---|---|
| 1 | ACHILLION PHARMACEUTICALS INC | 12.0% | $121.1m | 11,222,893 | -4% | reduced | |
| 2 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 11.2% | $113.1m | 7,088,651 | – | new |
| 3 | DYAX CORP | 10.1% | $102.2m | 2,717,618 | 7% | added | |
| 4 | AXOVANT SCIENCES LTD | 8.9% | $90.2m | 5,000,000 | 0% | held | |
| 5 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 6.8% | $69.1m | 2,564,553 | – | new |
| 6 | TGTX TG THERAPEUTICS INC | Healthcare | 3.3% | $33.6m | 2,813,779 | -10% | reduced |
| 7 | ZOGENIX INC | 3.3% | $33.2m | 2,253,237 | 34% | added | |
| 8 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 3.2% | $31.9m | 3,094,064 | 159% | added |
| 9 | ASND ASCENDIS PHARMA A S | Healthcare | 3.0% | $30.6m | 1,671,447 | 14% | added |
| 10 | REGULUS THERAPEUTICS INC | 3.0% | $30.4m | 3,482,924 | -14% | reduced | |
| 11 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 2.9% | $29.2m | 1,272,048 | -3% | reduced |
| 12 | DICERNA PHARMACEUTICALS INC | 2.9% | $28.8m | 2,428,571 | 0% | held | |
| 13 | COLL COLLEGIUM PHARMACEUTICAL INC | Healthcare | 2.3% | $23.6m | 857,683 | -45% | reduced |
| 14 | 2655787D BLUEPRINT MEDICINES CORP | 2.3% | $23.1m | 878,348 | 0% | held | |
| 15 | PROTEON THERAPEUTICS INC | 2.3% | $22.9m | 1,476,931 | -2% | reduced | |
| 16 | STRONGBRIDGE BIOPHARMA PLC | 2.0% | $20.4m | 2,690,702 | – | new | |
| 17 | AQUINOX PHARMACEUTICALS INC | 2.0% | $20.2m | 1,619,977 | 6% | added | |
| 18 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 2.0% | $20.2m | 2,212,036 | 53% | added |
| 19 | CIDARA THERAPEUTICS INC | 2.0% | $20.1m | 1,174,219 | -1% | reduced | |
| 20 | ALCOBRA LTD | 1.9% | $19.0m | 3,032,911 | 65% | added | |
| 21 | ARENA PHARMACEUTICAL S INC | 1.6% | $16.6m | 8,714,482 | – | new | |
| 22 | GLOBAL BLOOD THERAPEUTICS INC | 1.5% | $14.8m | 457,142 | 0% | held | |
| 23 | AIMT AIMMUNE THERAPEUTICS INC | 1.4% | $14.6m | 790,200 | 0% | held | |
| 24 | DIMENSION THERAPEUTICS INC | 1.2% | $12.3m | 1,087,930 | – | new | |
| 25 | ARDX ARDELYX INC | Healthcare | 1.0% | $10.4m | 571,444 | -46% | reduced |
| 26 | PRONAI THERAPEUTICS INC | 0.9% | $9.1m | 604,982 | 0% | held | |
| 27 | NTRA NATERA INC | Healthcare | 0.8% | $8.5m | 783,520 | -0% | held |
| 28 | TENX TENAX THERAPEUTICS INC | 0.8% | $7.8m | 2,389,700 | -11% | reduced | |
| 29 | VITAE PHARMACEUTICALS INC | 0.6% | $5.8m | 321,161 | 0% | held | |
| 30 | ZYNERBA PHARMACEUTICALS INC | 0.5% | $5.1m | 507,191 | -3% | reduced | |
| 31 | 2GT APPLIED GENETIC TECHNOL CORP | 0.5% | $4.8m | 236,059 | 95% | added | |
| 32 | NIVALIS THERAPEUTICS INC | 0.5% | $4.7m | 612,863 | 0% | held | |
| 33 | AKTX AKARI THERAPEUTICS PLC | 0.4% | $3.8m | 263,921 | 0% | held | |
| 34 | ARCA BIOPHARMA INC | 0.4% | $3.6m | 778,211 | -4% | reduced | |
| 35 | DERMA SCIENCES INC | 0.3% | $2.9m | 641,236 | – | new | |
| 36 | NEURODERM LTD | 0.2% | $2.5m | 144,671 | -66% | reduced | |
| 37 | AMPLIPHI BIOSCIENCES CORP | 0.0% | $213.0k | 53,600 | -18% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.